Medicines Co. (MDCO) Reports Q3 Loss of $0.70
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
The Medicines Company Reports Third-Quarter 2018 Results
November 8, 2018 7:00 AM ESTPARSIPPANY, N.J.--(BUSINESS WIRE)-- The Medicines Company (NASDAQ: MDCO) today reported its financial results for the third quarter ended September 30, 2018.
During the third quarter of 2018, we continued to advance inclisiran through Phase III trials and other, key development steps, said Clive Meanwell, M.D., Ph.D., Chief Executive Officer of The Medicines Company. We continue to be impressed by the blinded safety data emerging from the Phase III trials, and expect our clinical momentum to continue into 2019, moving toward anticipated clinical data readout early in the second half of... More
